Table 2.
Baseline, Follow‐Up, and Percent Change in Lipids, Apolipoproteins, and CEC
| Placebo (n=289) | Anacetrapib (n=285) | P Value* | |||||
|---|---|---|---|---|---|---|---|
| Week 0 | Week 24 | Median Percent Change | Week 0 | Week 24 | Median Percent Change | ||
| LDL‐C, mg/dL | 81 (68–94) | 75 (65–87) | −7.0 (−18.8 to 5.0) | 82 (69–94) | 42 (32–54) | −48.9 (−59.0 to −33.2) | <0.0001 |
| HDL‐C, mg/dL | 40 (34–47) | 45 (38–51) | 11.5 (2.1 to 26.3) | 40 (34–47) | 100 (82–117) | 145.2 (118.8 to 188.1) | <0.0001 |
| Triglycerides, mg/dL | 131 (101–194) | 130 (94–177) | −3.3 (−21.2 to 16.4) | 125 (93–172) | 114 (90–146) | −8.7 (−25.1 to 13.7) | 0.09 |
| ApoA‐I, mg/dL | 145 (130–159) | 145 (132–159) | 0 (−7.8 to 9.2) | 142 (127–157) | 207 (183–233) | 45.3 (31.6 to 59.6) | <0.0001 |
| ApoB, mg/dL | 88 (77–101) | 89 (77–101) | 0 (−8.1 to 11.7) | 86 (76–98) | 69 (60–78) | −20.9 (−30.7 to −8.7) | <0.0001 |
| Lipoprotein (a), nmol/L | 27 (12–66) | 31 (13–98) | 6.7 (−3.4 to 42.5) | 27 (10–59) | 16 (5–55) | −15.1 (−49.7 to 0) | <0.0001 |
| CEC normalized | 0.87 (0.77–1.01) | 0.84 (0.72–0.95) | −3.9 (−20.4 to 12.8) | 0.85 (0.76–0.97) | 0.89 (0.79–1.01) | 4.6 (−13.6 to 28.4) | 0.0001 |
Values are presented as median (interquartile range). ApoA‐I indicates apolipoprotein A‐I; ApoB, apolipoprotein B; CEC, cholesterol efflux capacity; HDL‐C, high‐density lipoprotein cholesterol; and LDL‐C, low‐density lipoprotein cholesterol.
a
P values for median percent change are obtained using Wilcoxon rank sum test assuming nonparametric distributions.